Closed guodudou closed 2 years ago
@guodudou Thanks for using DeMixT in your project. The inputs of DeMixT are the raw read counts from normal (non-tumor) and tumor samples. The normal samples are used as the reference. Ideally, the normal sample should come from the same organ of the same patient as the tumor sample. If such data are not available, you can also use the normal samples from TCGA or GTEx of the same cancer type to deconvolve the primary tumor samples.
The pipeline of DeMixT deconvolution involves the following steps:
After the above steps, the read counts from tumor and normal samples are fed into DeMixT as data.Y and data.N1, respectively. DeMixT returns a list object and let's call it res. res$pi are the component proportions. res$ExprT are the tumor specific expressions and res$ExprN1 are the normal specific expressions.
DeMixT can be run on metastatic tumor samples when a proper reference profile is available. But it is challenging to obtain such reference profile. We do not recommend to use the normal prostate tumor sample to deconvolve the metastatic castration-resistant prostate cancer samples.
More details about DeMixT can be found in the Bioconductor Vignette https://www.bioconductor.org/packages/release/bioc/vignettes/DeMixT/inst/doc/demixt.html. We will also upload a comprehensive tutorial about DeMixT to the github repository (https://github.com/wwylab/DeMixT) in the coming days and will let you know then. You can follow it for your own project.
@jiyunmaths Thank you so much for such detailed and constructive suggestions. It is an unfortunate for me to not be able to apply DeMixT to mCRPC samples. But this totally makes sense when think about the logic behind DeMixT deconvolution. Look forward to the comprehensive tutorial and utilizing DeMixT to primary tumor samples soon!
Hello,
I am interested in using DeMixT to perform cancer profile deconvolution of our RNAseq data. I have RSEM estimated read counts, what else should I do to the counts to be able to input them to DeMixT? Is the output ready for downstream statistical analysis or I have to perform additional normalization or transformation?
In addition, for the normal references, if our samples are Metastatic castration-resistant prostate cancer, should I still use normal prostate tissue as references? Can I start with read counts from GTEx or GDC or it is better to process from raw sequencing data to eliminate potential batch effect?
Thank you very much! I look forward to hearing from you.
Best, Wendy